Abbisko Cayman Limited (2256) AI Stock Analysis

• Market Cap: HK$10.45B
• Dividend Yield: N/A
• Average Volume (3M): 4.32M
• Price to Earnings (P/E): 54.9
• Beta (1Y): 1.38
• Revenue Growth: 23.37%
• EPS Growth: N/A
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.56
• Shares Outstanding: 680,105,350
• 10 Day Avg. Volume: 4,319,715
• 30 Day Avg. Volume: 4,318,146
• PEG Ratio: -1.02
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 6.07
• P/FCF Ratio: -150.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$22.08
• Price Target Upside: 51.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 55 Neutral
• Price Target: HK$14.50 ▼(-0.41% Downside)

Abbisko Cayman Limited's overall stock score is primarily influenced by its financial performance, which shows promising revenue growth and improved net income. However, technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation. The absence of earnings call insights and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates a successful execution of its business model, enhancing its market position and potential for future profitability.

Balance Sheet Health

A strong balance sheet with low debt enhances financial stability, providing flexibility for strategic investments and weathering economic fluctuations.

Cash Flow Improvement

Improved free cash flow indicates better cash management, which is crucial for funding operations and future growth without relying heavily on external financing.

Negative Factors

Negative Operating Cash Flow

Negative operating cash flow suggests challenges in generating cash from core operations, which could impact the company's ability to sustain growth and meet financial obligations.

Profitability Challenges

Ongoing profitability challenges, despite revenue growth, highlight issues in cost management and operational efficiency, potentially hindering long-term financial health.

Low Return on Equity

Low return on equity indicates inefficient use of shareholder funds, which could deter investment and affect the company's ability to raise capital in the future.

Abbisko Cayman Limited Business Overview & Revenue Model

Company Description

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Abbisko Cayman Limited primarily generates revenue through the development and commercialization of its pipeline of drug candidates. The company aims to move its drugs through clinical trials and obtain regulatory approvals, after which it can license these drugs to larger pharmaceutical companies or sell them directly. Key revenue streams include milestone payments from licensing agreements, royalties from commercialized products, and potential sales of its own marketed drugs. Strategic partnerships and collaborations with research institutions and other pharmaceutical companies also play a significant role in supporting its financial growth and development efforts.

Abbisko Cayman Limited Financial Statement Overview

Summary

Abbisko Cayman Limited has shown significant revenue growth and improved net income in 2024, indicating potential for future profitability. The balance sheet is strong with low debt and high equity, but the company must continue to manage its cash flows effectively to ensure long-term sustainability.

Income Statement

Abbisko Cayman Limited has shown a substantial increase in revenue in 2024 compared to 2023. The gross profit margin is 100% for both years, indicating all revenue contributes directly to profit before expenses. However, despite revenue growth, the company has struggled with profitability, as reflected by negative EBIT and EBITDA margins in recent years, although net income turned positive in 2024, indicating some improvement.

Balance Sheet

The company maintains a strong equity position with a very low debt-to-equity ratio, indicating limited reliance on debt financing. The equity ratio is high, suggesting strong financial stability. However, the return on equity is low due to prior years of negative net income, although there was a positive turn in 2024 which indicates some improvement in leveraging equity for profits.

Cash Flow

Operating cash flow remains negative, indicating that the business is not generating sufficient cash from operations. However, free cash flow has improved in 2024 compared to 2023, suggesting better cash management. The company has also reduced its capital expenditures, which might have helped in improving free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	618.84M	503.99M	19.06M	0.00	22.68M	0.00
Gross Profit	618.84M	503.99M	19.06M	0.00	22.68M	0.00
EBITDA	96.28M	-15.28M	-410.99M	-492.62M	-1.80B	-150.21M
Net Income	149.98M	28.30M	-431.58M	-498.29M	-1.81B	-706.81M
Balance Sheet
Total Assets	2.44B	2.11B	2.12B	2.49B	2.65B	665.97M
Cash, Cash Equivalents and Short-Term Investments	2.38B	2.01B	1.96B	2.35B	2.57B	636.66M
Total Debt	17.77M	24.29M	35.72M	45.58M	53.80M	4.31M
Total Liabilities	217.96M	148.71M	134.28M	143.16M	118.48M	1.77B
Stockholders Equity	2.22B	1.96B	1.98B	2.35B	2.54B	-1.10B
Cash Flow
Free Cash Flow	126.03M	-20.32M	-456.98M	-366.64M	-182.08M	-121.60M
Operating Cash Flow	129.00M	-12.92M	-444.73M	-343.90M	-169.74M	-117.56M
Investing Cash Flow	239.41M	-196.50M	378.52M	-216.57M	-1.46B	-11.25M
Financing Cash Flow	23.09M	-80.86M	-16.11M	-20.81M	2.10B	505.89M

Abbisko Cayman Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.56
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Neutral. The current price of 14.56 is below the 20-day moving average (MA) of 16.12, below the 50-day MA of 16.83, and above the 200-day MA of 10.48, indicating a neutral trend. The MACD of -0.73 indicates Positive momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 18.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2256.

Abbisko Cayman Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9966	―	HK$11.53B	45.14	13.34%	―	206.58%	―
2256	―	HK$10.45B	54.91	6.73%	―	23.37%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	―	HK$11.43B	17.53	35.80%	―	59.70%	239.97%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
2616	―	HK$9.18B	-20.28	-95.84%	―	-55.64%	-158.67%

Abbisko Cayman Limited Corporate Events

Abbisko Therapeutics Unveils Promising Preclinical Cancer Drug Findings

Abbisko Therapeutics announced promising preclinical findings for two of its drug candidates, the CDK4/2 inhibitor ABK-CDK-1 and the SMARCA2 PROTAC degrader ABK-SM2-1, at the 37th AACR-NCI-EORTC Conference. These developments highlight the company’s efforts to overcome limitations of existing cancer treatments, potentially enhancing its positioning in the oncology sector and offering new therapeutic options for patients.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko’s Pimicotinib Shows Promising Results in Phase III TGCT Trial

Abbisko Cayman Limited announced promising longer-term efficacy and safety outcomes from its Phase III MANEUVER trial of pimicotinib, a CSF-1R inhibitor, for treating tenosynovial giant cell tumour (TGCT). Presented at ESMO 2025, the results showed significant and durable tumor response improvements, with a favorable safety profile, suggesting pimicotinib’s potential as a leading therapy in TGCT management. These findings enhance the drug’s commercial prospects and Abbisko’s position in the oncology market.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Cayman Limited Grants Share Options to Directors and Employees

Abbisko Cayman Limited has announced the grant of 6,343,508 share options to three directors and certain employees under its Post-IPO Share Option Scheme. The options are subject to performance targets at both group and individual levels, with vesting scheduled over four years. This move aims to align the interests of the company’s leadership and employees with its strategic goals, potentially enhancing its competitive positioning in the pharmaceutical industry.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Cayman Limited Engages in Significant Wealth Management Subscriptions

Abbisko Cayman Limited has entered into agreements to subscribe for wealth management products with J.P. Morgan Securities plc, involving a total of USD 20 million. The transactions, which include a USD Callable Zero Coupon Note and a USD Note linked to the USDCNH rate, are considered discloseable under Hong Kong Listing Rules due to their aggregate value exceeding 5% but less than 25% of the company’s assets, necessitating reporting and announcement requirements.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko’s PD-L1 Inhibitor ABSK043 Gains IND Clearance for NSCLC Treatment

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the China National Medical Products Administration for its investigational oral PD-L1 inhibitor, ABSK043, in combination with Allist’s KRAS G12C inhibitor, glecirasib, for treating NSCLC patients with KRAS G12C mutation. This development marks a significant step in Abbisko’s strategic collaboration with Allist, aiming to enhance treatment options for NSCLC. The clearance allows for a Phase 2 clinical study to evaluate the safety and efficacy of the drug combination, potentially positioning Abbisko as a key player in the NSCLC treatment landscape.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Cayman Limited Reports Key Milestones in Drug Development for H1 2025

Abbisko Cayman Limited has announced significant advancements in its drug development pipeline for the first half of 2025. The company’s lead asset, pimicotinib, has reached a major milestone with the acceptance of its NDA by the China NMPA for the treatment of tenosynovial giant cell tumor, and Merck has exercised a global commercialization option for the drug. Additionally, Abbisko has initiated a registrational study for irpagratinib in hepatocellular carcinoma and received Breakthrough Therapy Designation from the China NMPA, underscoring its potential as a precision treatment for HCC.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Cayman Limited Enhances Governance with New Nomination Committee

Abbisko Cayman Limited has established a Nomination Committee to enhance its corporate governance structure. The committee, formed by the board of directors, will consist of at least three members, with a majority being independent non-executive directors, and will include at least one member of a different gender. This move is expected to strengthen the company’s decision-making processes and align with best practices in corporate governance, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.